Comparative Approaches to Drug Pricing.

IF 21.4 1区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
So-Yeon Kang, Ge Bai, Michael J DiStefano, Mariana P Socal, Farah Yehia, Gerard F Anderson
{"title":"Comparative Approaches to Drug Pricing.","authors":"So-Yeon Kang,&nbsp;Ge Bai,&nbsp;Michael J DiStefano,&nbsp;Mariana P Socal,&nbsp;Farah Yehia,&nbsp;Gerard F Anderson","doi":"10.1146/annurev-publhealth-040119-094305","DOIUrl":null,"url":null,"abstract":"<p><p>The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.</p>","PeriodicalId":50752,"journal":{"name":"Annual Review of Public Health","volume":"41 ","pages":"499-512"},"PeriodicalIF":21.4000,"publicationDate":"2020-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1146/annurev-publhealth-040119-094305","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-publhealth-040119-094305","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 14

Abstract

The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.

药品定价的比较方法。
美国主要依靠市场力量来决定药品价格,而大多数其他工业化国家使用各种方法来确定药品价格。在大多数工业化国家,品牌药品公司拥有专利和市场独占期。在此期间,由于没有其他国家存在的政府价格控制机制,制药公司被允许在美国设定自己喜欢的价格。参保患者通常按标价支付一定比例的费用,费用分摊会产生一定的压力,迫使他们降低标价。药房福利管理人员通过向制药公司提供有利的处方位置和较少的使用控制,与制药公司谈判以降低价格。然而,与其他国家控制品牌药价格的方法相比,这些方法似乎效果较差,因为美国的价格要高得多。其他工业化国家采用各种形式的定价和价格管制,例如外部参考定价、治疗估价和保健技术评估,以确定适当的价格。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annual Review of Public Health
Annual Review of Public Health 医学-公共卫生、环境卫生与职业卫生
CiteScore
26.60
自引率
1.40%
发文量
36
审稿时长
>12 weeks
期刊介绍: The Annual Review of Public Health has been a trusted publication in the field since its inception in 1980. It provides comprehensive coverage of important advancements in various areas of public health, such as epidemiology, biostatistics, environmental health, occupational health, social environment and behavior, health services, as well as public health practice and policy. In an effort to make the valuable research and information more accessible, the current volume has undergone a transformation. Previously, access to the articles was restricted, but now they are available to everyone through the Annual Reviews' Subscribe to Open program. This open access approach ensures that the knowledge and insights shared in these articles can reach a wider audience. Additionally, all the published articles are licensed under a CC BY license, allowing users to freely use, distribute, and build upon the content, while giving appropriate credit to the original authors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信